How GLP-1RA drugs are reshaping patient physiology and the future of oncology

<p>The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. [&#8230;]</p> <p>The post <a href="https://cancerletter.com/trials-and-tribulations/20251031_4/"…